Późnośredniowieczna nadmorska osada rybacka w Pleśnej, gm. Będzino, pow. Koszalin

The article is aimed at presentation of different aspects related to discovery and analysis of materials from a late medieval seaside fishing village at Pleśna. It presents a scope of archaeological rescue excavations and assesses factors responsible for destruction of a cliff shore along with the settlement placed on top of it. Additionally, the article brings about analysis of excavated materials. The settlement chronology and developmentof the Pleśna region occupation is  based upon archaeological evidence and historical sources.The article is aimed at presentation of different aspects related to discovery and analysis of materials from a late medieval seaside fishing village at Pleśna. It presents a scope of archaeological rescue excavations and assesses factors responsible for destruction of a cliff shore along with the settlement placed on top of it. Additionally, the article brings about analysis of excavated materials. The settlement chronology and developmentof the Pleśna region occupation is  based upon archaeological evidence and historical sources

Optimization of bend stiffeners of a suspended inter-array power cable between two floating offshore wind turbines

The concept of a suspended inter-array power cable assumes that the cable floats within the water column instead of being laid on the seabed. This setup requires additional equipment, such as buoyancy modules or buoys, to achieve the desired cable configuration. The implementation of buoyancy modules introduces abrupt changes in stiffness between the cable sections with clamped-on buoyancy modules and bare cable sections. Large stiffness variations can negatively impact cable bending, causing excessive curvature and fatigue damage. In order to form a smooth transition in stiffness between the buoyancy sections and the bare cable, bend stiffeners can be equipped. The study aims to optimize the bend stiffener design for a representative suspended power cable between two floating offshore wind turbines (FOWTs). The inter-array power cable system is simulated in OrcaFlex. Two parameters, including the outer diameter and the length of the bend stiffener, are adjusted to generate different cases. Eight environmental conditions are applied to the dynamic analysis of the cases. The fitness factor approach is used as a criterion to assess the overall performance of different bend stiffener designs. Adjusting the outer diameter of bend stiffeners clearly influences the maximum effective tension and the minimum bending radius by changing the stiffness profile of the bend stiffener and its submerged weight. In the investigated range of parameters, increasing the overall length of bend stiffeners is found to be less effective than adjusting the outer diameter of the bend stiffener.publishedVersio

Effects of dietary nitrate supplementation on symptoms of acute mountain sickness and basic physiological responses in a group of male adolescents during ascent to Mount Everest Base Camp

The purpose of this study was to investigate the effects of dietary nitrate supplementation, in the form of beetroot juice, on acute mountain sickness (AMS) symptoms and physiological responses, in a group of young males trekking to Mount Everest Base Camp (EBC). Forty healthy male students (mean age (SD): 16 (1) yrs) trekked to EBC over 11 days. Following an overnight fast, each morning participants completed the Lake Louise AMS questionnaire and underwent a series of physiological tests: resting blood pressure as well as resting and exercising heart rate, respiratory rate, and peripheral oxygen saturation. The exercise test consisted of a standardised 2-minute stepping protocol and measurements were taken in the last 10 seconds. Participants in the intervention arm of the study consumed 140 ml of concentrated beetroot juice daily, containing approximately 10 mmoles of nitrate, while those in the control arm consumed 140 ml of concentrated blackcurrant cordial with negligible nitrate content. Drinks were taken for the first seven days at high altitude (days 2 to 8), in two equal doses; one with breakfast, and one with the evening meal. Mixed modelling revealed no significant between-groups difference in the incidence of AMS (Odds Rationitrate vs. control: 1.16 (95% CI: 0.59; 2.29)). Physiological changes occurring during ascent to high altitude generally were not significantly different between the two groups (Model Coef (95% CI) – average difference nitrate vs. control: systolic blood pressure, 0.16 (-4.47; 4.79); peripheral oxygen saturation, 0.28 (-0.85; 1.41); heart rate, -0.48 (-8.47; 7.50) (Model Coef (95% CI) – relative difference nitrate vs. control: ventilatory rate, 0.95 (0.82; 1.08)). Modelling revealed that diastolic blood pressure was 3.37 mmHg (0.24; 6.49) higher for participants in the beetroot juice, however this difference was no larger than that found at baseline and no interaction effect was observed. Supplementation with dietary nitrate did not significantly change symptoms of AMS or alter key physiological variables, in a group of adolescent males during a high altitude trekking expedition. There was no evidence of harm from dietary nitrate supplementation in this context. Given the wide confidence intervals in all models, a larger sample size would be required to exclude a false negative result. Our data suggest that prolonged oral nitrate supplementation is safe and feasible at altitude but has little physiological or clinical effect

Ligelizumab for Chronic Spontaneous Urticaria

Background: In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal anti-IgE antibody. Data are limited regarding the dose–response relationship of ligelizumab and the efficacy and safety of ligelizumab as compared with omalizumab and placebo in patients who have moderate-to-severe chronic spontaneous urticaria that is inadequately controlled with H1-antihistamines at approved or increased doses, alone or in combination with H2-antihistamines or leukotriene-receptor antagonists. Methods: In a phase 2b dose-finding trial, we randomly assigned patients to receive ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab. Disease symptoms of hives, itch, and angioedema were monitored by means of weekly activity scores. The main objective was to determine a dose–response relationship for the complete control of hives (indicated by a weekly hives-severity score of 0, on a scale from 0 to 21, with higher scores indicating greater severity); the primary end point of this response was assessed at week 12. Complete symptom control was indicated by a weekly urticaria activity score of 0 (on a scale from 0 to 42, with higher scores indicating greater severity). Safety was analyzed throughout the trial. Results: A total of 382 patients underwent randomization. At week 12, a total of 30%, 51%, and 42% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of hives, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group. A dose–response relationship was established. At week 12, a total of 30%, 44%, and 40% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of symptoms, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group. In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged. Conclusions: A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT02477332. opens in new tab.

Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study

Background Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care therapy. Objective To evaluate the long-term safety and re-treatment efficacy of ligelizumab 240 mg in patients who completed the core study and extension study. Methods This open-label, single-arm, long-term Phase 2b extension study was designed to assess patients who were previously administered various doses of ligelizumab, omalizumab or placebo in the Phase 2b, dose-finding core study and who presented with active disease after Week 32. In the extension study, patients received ligelizumab 240 mg subcutaneously every 4 weeks, for 52 weeks and were monitored post-treatment for 48 weeks. Results Overall, ligelizumab was well-tolerated with no newly identified safety signals. A total of 95.4% (226/237) screened patients received ligelizumab 240 mg in the extension study; 84.1% (190/226) of patients experienced at least one treatment-emergent adverse event. Most reported events were mild (41.6%) or moderate (35.8%) and mostly unrelated to the study treatment. At Week 12, 46.5% of patients had a complete response increasing to 53.1% after 52 weeks. Following 52 weeks of extension study treatment, 75.8% (95% confidence interval, 69.9, 81.3) of patients had cumulative complete responses. The median time to relapse in complete responders was 38 weeks. Conclusion The long-term safety profile of ligelizumab 240 mg in patients with chronic spontaneous urticaria was consistent with the core study and re-treatment efficacy was shown. Trial Registration: ClinicalTrials.gov Identifier: NCT02477332 and NCT02649218

Depositional environments and source rock potential of some Upper Palaeozoic (Devonian) coals on Bjørnøya, Western Barents shelf

Upper Palaeozoic strata are potential sources for hydrocarbon plays on the Norwegian Barents Shelf. The island of Bjørnøya (Bear Island) is located on the western margin of the Barents Shelf and represents an exposed part of the Stappen High, which makes it an excellent location to investigate the source rock potential of this succession. Here, we investigate the organic geochemical composition and source rock potential of coals and organic-rich mudstones of Late Devonian to middle Permian ages. The thermal maturity of the analysed samples ranges from mature to overmature with some samples being in the late oil generation window, and thus exhibiting higher maturities than age and facies equivalent strata in central Spitsbergen in the NW corner of the Barents Shelf and on the Finnmark Platform to the south. The high maturities and thermal cracking may thus have negatively affected the applied isoprenoid and biomarker-based source facies parameters, which potentially inhibit correct source facies interpretation. However, our results and comparisons with previous studies indicate that the vitrinite- and inertinite-dominated humic coals occurring in the lower part of the succession formed by the accumulation of peat in fluvially-influenced, humid wetlands at paleo-equatorial latitudes during a pronounced episode of rifting in the Late Devonian (Famennian) to earliest Carboniferous (Mississippian). Our source rock evaluation indicates a good potential for liquid hydrocarbon generation for the coals of the Upper Devonian Røedvika Formation prior to maturation. The oil-prone organic matter of these coals is primarily considered as terrestrial and non-aqueous. Because of renewed rifting in the middle Carboniferous combined with a shift to arid climatic conditions, as well as an environmental change from dominantly terrestrial and marginal marine clastic to marine carbonate platform environments, the accumulation of wetland peats effectively came to an end. Thus, the overlying Carboniferous and Permian strata generally seems to yield poor to no hydrocarbon generation potentia